Eyerising International list multiple errors and inaccuracies in the article:
• The authors incorrectly alleged the Eyerising device did not meet safety standards it claimed
• The authors tested devices to the wrong ANSI standards
• The authors failed to mention the Eyerising Device’s proven safety record
• The authors inaccurately reported a case study involving the Eyerising device.
Melbourne Australia, 31 January 2024:
Eyerising International, the Australian company, which is the legal manufacturer of the Eyerising Myopia Management Device, a repeated low-level red-light (RLRL) device, maintain that their device was misrepresented in an article recently published in the Ophthalmic & Physiological Optics (OPO) Journal, titled, “Red light instruments for myopia exceed safety limits”, authored by Lisa A. Ostrin and Alexander W. Schill.
The authors of the OPO article several times referred to the Eyerising Myopia Management Device in a negative and inaccurate manner; despite having not tested the device or contacted Eyerising International for information or comment.
OPO to publish Eyerising’s letter addressing inaccuracies
Eyerising International have spoken to the Editor-in-Chief of the OPO Journal, and he has agreed to give the company the right of reply to Dr Astin’s article and to publish a ‘letter to the editor’ addressing the inaccuracies and misrepresentations in Dr Ostrin’s article.
Our issues with the Dr Astin’s article are addressed below.